Accelerated intermittent theta burst stimulation targeting personalized fronto-parietal control network improves core symptoms of autism spectrum disorder: a double-blind, randomized controlled trial.

This was a randomised controlled trial — people were assigned to treatments by chance, which is the most reliable way to tell whether a treatment itself caused a change.

It involved 67 people — a modest group, enough to be interesting but not enough to settle a question on its own.

The study ran for 12 weeks. That is a short window, so it says nothing about whether the effects last.

The abstract does not include a conclusions section, so this page does not state what the researchers concluded.

This is a plain-language summary of one paper's abstract, not medical advice. Talk to your child's clinician before changing anything.

Journal: Molecular psychiatry

Year: 2026

Design: Randomized Controlled Trial

Participants: 67

Age range: 6-30 years

Intervention: a double-blind, randomized controlled trial

Authors: Qi Liu, Jiawei Zhang, Xinyu Duan, Ping Zhang, Yang Yang, Guanzhong Yao, Bulideerqing Jiaerheng, Xiao-Jing Shou, Yong He, Kaiyue Han, Meixiang Jia, Lifang Wang, Weijun Gong, Wuxiang Xie, Kai Sun, Danhong Wang, Xiao-Dan Wu, Hua Cao, Hao Zhang, Hesheng Liu

Autism Spectrum Disorder (ASD) presents a substantial global challenge, yet no pharmacological treatments effectively target its core symptoms, especially in individuals with severe cognitive or adaptive impairments. This double-blind, sham-controlled, randomized clinical trial assessed accelerated intermittent theta burst stimulation (iTBS) targeting the personalized fronto-parietal network (FPN) in ASD. Participants (6-30 years) were randomized in a 2:1 ratio to active or sham iTBS (three daily sessions, 1800 pulses/session) over 12 weeks (324k pulses) alongside behavioral training. The primary outcome was defined as the response rate, charaterized by a ≥ 1-point reduction in ADOS-2 SA at week 12. Of 132 individuals screened, 67 were randomized (mean age 10.04 ± 4.22 years; 88.1% male; all with cognitive/adaptive delays), with 59 completing the study. Active iTBS resulted in a significantly higher response rate (55% vs. 29%) and higher symptom improvement than sham (cohen's d = -0.53), with mild local pain in only 5% of iTBS group. In the profound autism subgroup, the active group exhibited language improvement alongside amelioration of core symptoms. These findings suggest that prolonged, accelerated FPN-targeted iTBS is a safe and efficacious intervention for severe ASD, offering a promising therapeutic approach.Registration ClinicalTrials.gov Identifier: NCT05890846.

Molecular psychiatry, 2026

PMID 41986743

DOI 10.1038/s41380-026-03596-2

This record was extracted from the paper's PubMed abstract and metadata. Full-text methods and risk-of-bias details were not reviewed.